2009
DOI: 10.1016/j.jns.2009.06.004
|View full text |Cite
|
Sign up to set email alerts
|

Multiple sclerosis associated fatigue during natalizumab treatment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

4
25
2
7

Year Published

2010
2010
2016
2016

Publication Types

Select...
6
3

Relationship

1
8

Authors

Journals

citations
Cited by 56 publications
(38 citation statements)
references
References 34 publications
4
25
2
7
Order By: Relevance
“…Given the marked reduction of clinical and MRI parameters for inflammatory activity in comparison to IFN and GA, this effect could be attributable to a more pronounced decrease of inflammatory CNS activity with NTZ. Our results in longer-term NTZ-treated patients complement results from a previous short-term prospective study [10] . Findings for the control group were similar to previous analyses from the same database [3] .…”
supporting
confidence: 86%
See 1 more Smart Citation
“…Given the marked reduction of clinical and MRI parameters for inflammatory activity in comparison to IFN and GA, this effect could be attributable to a more pronounced decrease of inflammatory CNS activity with NTZ. Our results in longer-term NTZ-treated patients complement results from a previous short-term prospective study [10] . Findings for the control group were similar to previous analyses from the same database [3] .…”
supporting
confidence: 86%
“…Findings for the control group were similar to previous analyses from the same database [3] . Fatigue was independent from most important patient characteristics, which underlines that we examined a common construct of fatigue [3,[8][9][10] . A reduction of fatigue during NTZ treatment represents a relevant, additional treatment benefit for improved quality of life.…”
mentioning
confidence: 97%
“…13,14,24,25 ENER-G is the largest prospective study to evaluate fatigue and cognition during natalizumab treatment, and to examine correlations between the two. Both fatigue and cognitive decline can be debilitating for MS patients.…”
Section: Discussionmentioning
confidence: 99%
“…1 Furthermore, some natalizumab-treated patients experience subjective improvement in functional status, mood, fatigue level, and cognitive function. [2][3][4][5][6] Natalizumab is administered as a 300-mg intravenous infusion every 4 weeks. The mean half-life of natalizumab in MS patients is 11 days (SD 4 days).…”
mentioning
confidence: 99%